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Background
The  health  of  populations  in  developed  countries  has 
never  been  better.  Within  the  past  century,  the  life 
expectancy of humans has increased from 40 years to 74 
years.  Correspondingly,  the  public  health  burden  has 
shifted from infectious diseases to autoimmune diseases 
[1]  and  to  diseases  associated  with  lifestyle  and  aging, 
such  as  diabetes,  cardiovascular  disease,  cancer  and 
Alzheimer’s disease (AD).
AD is the most common form of dementia. Because 
age is a major risk factor of AD, the prevalence of this 
incurable, degenerative and terminal disease is expected 
to rise dramatically over the next decades. It is estimated 
there will be over 80 million AD patients by 2050 [2-4]. 
Given the change in demographic structure and the rise 
of life expectancy in developing countries, AD is likely to 
have a major socioeconomic impact.
The progression of AD is gradual, with the subclinical 
stage of illness believed to span several decades [5,6]. The 
pre-dementia  stage,  also  termed  mild  cognitive 
impairment (MCI), is characterized by subtle symptoms 
that  may  affect  complex  daily  activities.  These  include 
memory  loss,  impairment  of  semantic  memory  and 
problems with executive functions, such as attentiveness, 
planning,  flexibility  and  abstract  thinking  [6].  MCI  is 
considered as a transition phase between normal aging 
and AD. MCI confers an increased risk of developing AD 
[7],  although  the  state  is  heterogeneous  with  several 
possible outcomes, including even improvement back to 
normal cognition [8].
Despite there being no currently available therapy to 
prevent  AD,  early  disease  detection  would  still  be  of 
utmost importance for delaying the onset of the disease 
with pharmacological treatment and/or lifestyle changes, 
assessing the efficacy of potential AD therapeutic agents, 
or  monitoring  disease  progression  more  closely  using 
medical imaging. Recent research has thus concentrated 
on  obtaining  biomarkers  to  identify  features  that 
differentiate between the individuals with MCI who will 
develop  AD  (progressive  MCI)  and  individuals  with 
stable MCI and healthy elderly people.
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it is expected that their integration will improve early 
detection as well as our understanding of the disease.
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AD is characterized by deposition of amyloid β (Aβ) in 
the  extracellular  space.  Given  that  the  allele  ε4  of  the 
apolipoprotein E gene (APOE4), the major genetic risk 
factor of AD [9], leads to excess Ab accumulation before 
the first symptoms of AD [10], it was believed that Aβ 
also  has  a  pathogenic  role  [11].  However,  it  was  later 
shown that Aβ accumulation in plaques is insufficient to 
cause the neuronal cell death observed in AD, and that 
neuronal protein tau is essential for neurodegeneration in 
AD [12,13].
The 40- or 42-peptide amyloid β (Aβ1-40/42), total tau and 
tau phosphorylated at Thr181 (P-tau181P), all of which can 
be  measured  from  cerebrospinal  fluid  (CSF),  are  well 
established markers of AD [14]. A recent study [15] used 
an unsupervised mixture modeling approach, indepen-
dent of AD diagnosis, to identify a molecular signature 
derived from a mixture of Aβ1-42 and P-tau181P that was 
associated with AD. The AD signature identified subjects 
who progress from MCI to AD with high sensitivity and 
was  surprisingly  also  present  in  a  third  of  cognitively 
normal  subjects,  suggesting  that  AD  pathology  may 
occur earlier than previously thought.
CSF  has  severe  drawbacks  for  routine  diagnosis 
because of the invasiveness and potential side effects of 
sample collection. However, attempts to use Aβ or tau as 
measured from plasma as potential predictive markers of 
AD have so far not been successful [16-18]. Among the 
available non-invasive techniques, brain imaging methods, 
such as magnetic resonance imaging or positron emission 
tomography, can identify cerebral pathologies specifically 
associated  with  early  progression  to  AD  [18,19].  At 
present, it is unclear how atrophy in the hippocampus 
and hypometabolism in the inferior parietal lobules, as 
observed  in  these  studies,  relate  to  the  disease 
pathophysiology and the existing CSF-derived markers.
High-throughput strategies to identify novel 
blood-based biomarkers
The ‘omics’ revolution has given us the tools needed for a 
discovery-driven  strategy  to  identify  new  molecular 
biomarkers from biofluids, cells or tissues. Lessons have 
been  learned  about  the  statistical  and  study  design 
precautions  needed  when  applying  such  strategies  of 
measuring  large  numbers  of  molecular  components 
[20,21].  The  major  advantage  of  high-throughput 
approaches  over  more  targeted  hypothesis-driven 
strategies  is  their  capacity  to  collect  large  amounts  of 
information  about  a  specific  phenotype  or  disease 
condition in an unbiased manner.
Recent quantitative analysis of 120 plasma proteins [22] 
identified  18  signaling  proteins  as  potential  predictive 
biomarker  candidates,  which  were  mainly  associated 
with  reduced  hematopoiesis  and  inflammation  during 
presymptomatic  AD.  In  a  subsequent  larger  serum 
proteomics  study  by  another  research  team  [23],  a 
multiplex protein immunoassay was used to classify AD 
and controls with high sensitivity and specificity. Notably, 
the  overlap  of  the  marker  proteins  between  the  two 
studies was minimal, and neither of the studies [22,23] 
were  validated  in  an  independent  cohort.  Blood 
mononuclear  cells  have  also  been  considered  as  a 
potential source of biomarkers. Preliminary studies using 
transcriptional and microRNA profiling in AD patients 
and  healthy  controls  suggest  that  a  distinct  AD-
associated expression signature can be identified [24,25]. 
The major changes in blood mononuclear cells include 
diminished expression of genes involved in cytoskeletal 
maintenance, DNA repair and redox homeostasis.
Profiling  of  small  molecules  (metabolites)  is  also  a 
promising  way  to  search  for  new  AD  biomarkers. 
Concentration changes of specific groups of circulating 
metabolites may be sensitive to pathogenically relevant 
factors,  such  as  genetic  variation,  diet,  age  or  gut 
microbiota  [26-29].  The  study  of  high-dimensional 
chemical  signatures  as  obtained  by  metabolomics  may 
therefore  be  a  powerful  tool  for  characterization  of 
complex  phenotypes  affected  by  both  genetic  and 
environmental factors [30]. No metabolic markers have 
been reported so far for AD, but several projects aiming 
to  discover  serum-derived  metabolic  markers  are 
ongoing, including HUSERMET [31] and PredictAD [32].
Towards systems medicine in AD
Large amounts of information gathered by various high-
throughput  technologies  come  at  a  price.  The  data, 
usually  corresponding  to  different  aspects  of  disease 
pathology,  need  to  be  integrated  in  a  meaningful  way. 
Such  data  integration  does  not  encompass  only 
informatics  and  statistics;  for  example,  it  includes  the 
development of tools not only for storing and mining the 
data,  but  also  modeling  of  the  data  in  the  context  of 
disease  pathophysiology.  In  AD,  the  adoption  of  a 
systems approach is particularly challenging since even at 
the  molecular  level  the  disease  pathogenesis  is  highly 
complex, covering multiple spatial and temporal scales. 
As discussed below, this complexity demands that studies 
look beyond the pathways.
The  genetics  of  late-onset  AD  is  complex,  although 
several of the common risk alleles other than APOE are 
involved in production, aggregation and removal of Aβ 
[33].  Several  of  the  associated  single  nucleotide 
polymorphisms  produce  a  synonymous  codon  change; 
that is, without any change in the corresponding protein 
sequence [33,34]. Such synonymous codon changes may 
not affect gene expression but can affect protein folding 
and thus the structure and function of the protein [35] by 
affecting  translational  accuracy  or  co-translational 
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secondary structure [36].
The  importance  of  understanding  the  structural  and 
spatial context of AD-associated proteins and peptides is 
underlined by recent studies of truncated Aβ fragments 
(Aβ17-40/42 [37] and Aβ11-40/42 [38]), which are nonamyloido-
genic and thus were believed to be harmless bystanders 
in  amyloid  plaques  found  in  AD.  Molecular  dynamics 
simulations  of  truncated  Aβ  peptides,  followed  up  by 
functional studies, suggest that these peptides are mobile 
in biological membranes and may dynamically form ion 
channels [39]. Such ion channels may be toxic, as they 
affect the uptake of ions such as calcium into the cells. 
The  reason  that  they  can  appear  with  aging,  in  some 
individuals,  remains  to  be  established.  One  possible 
explanation is the varying composition of neuronal lipid 
membranes,  specifically  plasmalogens,  ether  phospho-
lipids that are enriched in polyunsaturated fatty acids and 
are  abundant  in  brain  [40,41].  Plasmalogens  affect 
membrane fluidity and protein mobility [40,42] and they 
are found to be diminished in early AD [43-45] and in 
normal aging [46]. In addition, plasmalogens, via their 
vinyl-ether  bond,  act  as  endogenous  antioxidants  to 
protect  cells  from  reactive  oxygen  species,  and 
their reduction in AD is thus in line with the hypothesis 
implicating the role of oxidative stress in AD pathogenesis 
[47].  Taking  these  results  together,  one  would  expect 
that  age-related  and  disease-related  changes  in 
membrane  lipid  composition  would  also  affect  the 
mobility  of  Aβ  peptides,  including  dynamics  of  their 
self-assembly.
Lipidomics tools are now available for detailed studies 
of molecular lipids in cells and biofluids [48]. Molecular 
profiling,  combined  with  biophysical  modeling  of 
membrane systems – for example, to study β-sheet self 
assembly [49,50], lipid membranes [51] or lipoproteins 
[52] – thus offer an opportunity to link the molecular 
pathway  changes  with  cell-  and  tissue-level  physiology 
and structure. This may not only lead to new concepts in 
disease  pathogenesis,  but  also  suggest  new  diagnostic 
and therapeutic avenues.
Bioinformatics tools enabling a systems medicine 
approach to AD
Many  tools  are  available  for  mining  of  heterogeneous 
biological data, although the focus of such tools and the 
challenges being addressed by them have largely been in 
the  domains  of  molecular  interactions  and  biological 
pathways [53]. There is still a gap between the molecular 
representations  of  disease-related  processes  and  the 
clinical disease. In this context, the measurement of traits 
that  are  modulated  but  not  encoded  by  the  DNA 
sequence,  commonly  referred  to  as  intermediate 
phenotypes  [54],  may  be  of  particular  interest.  These 
intermediate phenotypes not only include biochemical, 
genomic or functional traits, as discussed above, but also 
an  individual’s  microbial  (gut  microflora)  and  social 
traits.  The  bioinformatic  strategies  to  manage  the 
disease-associated  genetic,  molecular  and  phenotypic 
data would thus aim to link the biological networks with 
specific  intermediate  phenotypes  relevant  to  clinical 
disease by using a suite of models (Figure 1). The models, 
Figure 1. A conceptual bioinformatic framework for enabling biomarker discovery and diagnosis in Alzheimer’s disease. The biophysical, 
biochemical and statistical models are used to integrate information from intermediate phenotypes, such as those obtained from magnetic 
resonance imaging (MRI) or from serum metabolomics, with the molecular networks. The models relate changes in specific components of the 
networks with the specific changes in measured intermediate phenotypes (red and blue lines, respectively). These models then inform biomarker 
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described  above,  together  with  the  intermediate 
phenotype  data,  could  be  used  for  discovery  of  new 
biomarkers of pathophysiological relevance.
Intermediate phenotypes, such as brain image data or 
serum metabolomic profiles, may also facilitate linking of 
the  findings  from  experimental  disease  models  with 
clinical  phenotypes.  This  is  particularly  relevant  for 
diseases in which animal models are difficult to validate, 
such as in diseases of the central nervous system. One 
recent example is a metabolomic study of Huntington’s 
disease [55], for which early disease markers were sought 
in  patients  and  a  transgenic  mouse  model.  Clear 
differences in metabolic profiles between transgenic mice 
and wild-type littermates were observed, with a trend for 
similar differences between human patients and control 
subjects.  The  data  thus  raise  the  prospect  of  a  robust 
molecular  definition  of  progression  of  Huntington’s 
disease  before  symptom  onset  and,  if  validated  in  a 
genuinely  prospective  manner,  these  biomarker 
trajectories  could  facilitate  the  development  of  useful 
therapies for this disease. A similar strategy could also be 
useful in the studies involving transgenic mouse models 
of AD [56].
Conclusions
The pathogenesis of AD is complex and there is a strong 
case for integrating information across multiple physio-
logical  levels,  from  molecular  profiling  (metabolomics, 
lipidomics,  proteomics  and  transcriptomics)  and  brain 
imaging  to  cognitive  assessments.  The  adoption  of  a 
systems approach to study AD will demand integration of 
heterogeneous data (such as molecular and image data) 
and  studies  of  disease-associated  molecules  and  their 
assemblies beyond the pathway-centric view. To address 
data integration, sophisticated approaches are needed to 
segment the image data [57] and study their dependencies 
on  molecular  changes  in  the  same  subjects.  To  take 
studies  beyond  pathways,  computational  models  are 
needed  to  study  AD-associated  molecules  and  their 
interactions in the spatial and temporal context. Given 
that  data  acquired  at  different  levels  may  carry 
complementary information about early AD pathology, it 
is  expected  that  their  integration  will  improve  early 
detection as well as our understanding of the disease.
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